{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T03:59:09Z","timestamp":1773115149584,"version":"3.50.1"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T00:00:00Z","timestamp":1600128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Itraconazole remains a first-line antifungal agent for certain fungal infections in children, including allergic bronchopulmonary aspergillosis (ABPA) and sporotrichosis, but poor attainment of therapeutic drug levels is frequently observed with available oral formulations. A formulation of \u2018SUper BioAvailability itraconazole\u2019 (SUBA-itraconazole; Lozanoc\u00ae) has been developed, with adult studies demonstrating rapid and reliable attainment of therapeutic levels, yet paediatric data are lacking.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess the safety, efficacy and attainment of therapeutic drug levels of the SUBA-itraconazole formulation in children.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A single-centre retrospective cohort study was conducted, including all patients prescribed SUBA-itraconazole from May 2018 to February 2020. The recommended initial treatment dose was 5\u2009mg\/kg twice daily (to a maximum of 400\u2009mg\/day) rounded to the nearest capsule size and 2.5\u2009mg\/kg\/day for prophylaxis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Nineteen patients received SUBA-itraconazole and the median age was 12\u2009years. The median dose was 8.5\u2009mg\/kg\/day and the median duration was 6\u2009weeks. Indications included ABPA (16 patients), sporotrichosis (1), cutaneous fungal infection (1) and prophylaxis (1). Of patients with serum levels measured, almost 60% (10\/17) achieved a therapeutic level, 3 with one dose adjustment and 7 following the initial dose. Adherence to dose-adjustment recommendations amongst the seven patients not achieving therapeutic levels was poor. Of patients with ABPA, 13\/16 (81%) demonstrated a therapeutic response in IgE level. SUBA-itraconazole was well tolerated with no cessations related to adverse effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>SUBA-itraconazole is well tolerated in children, with rapid attainment of therapeutic levels in the majority of patients, and may represent a superior formulation for children in whom itraconazole is indicated for treatment or prevention of fungal infection.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaa382","type":"journal-article","created":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T19:06:37Z","timestamp":1597604797000},"page":"249-252","source":"Crossref","is-referenced-by-count":26,"title":["Clinical experience with SUBA-itraconazole at a tertiary paediatric hospital"],"prefix":"10.1093","volume":"76","author":[{"given":"Joanne","family":"Abbotsford","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Perth Children\u2019s Hospital, Nedlands, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A","family":"Foley","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Perth Children\u2019s Hospital, Nedlands, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoy","family":"Goff","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Perth Children\u2019s Hospital, Nedlands, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asha C","family":"Bowen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Perth Children\u2019s Hospital, Nedlands, Western Australia, Australia"},{"name":"Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Western Australia, Australia"},{"name":"University of Western Australia, School of Medicine, Perth, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher C","family":"Blyth","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Perth Children\u2019s Hospital, Nedlands, Western Australia, Australia"},{"name":"Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Western Australia, Australia"},{"name":"University of Western Australia, School of Medicine, Perth, Western Australia, Australia"},{"name":"Department of Microbiology, PathWest Laboratory Medicine, QEII Medical Centre, Royal Perth Hospital and Fiona Stanley Hospital, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel K","family":"Yeoh","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Perth Children\u2019s Hospital, Nedlands, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,9,15]]},"reference":[{"key":"2020121103534544800_dkaa382-B1","doi-asserted-by":"crossref","first-page":"i33","DOI":"10.1093\/jac\/dki222","article-title":"The place for itraconazole in treatment","volume":"56 Suppl 1","author":"Maertens","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2020121103534544800_dkaa382-B2","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.chest.2018.01.005","article-title":"A randomized trial of itraconazole vs prednisolone in acute-stage allergic bronchopulmonary aspergillosis complicating asthma","volume":"153","author":"Agarwal","year":"2018","journal-title":"Chest"},{"key":"2020121103534544800_dkaa382-B3","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/imj.12600","article-title":"Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014","volume":"44","author":"Chau","year":"2014","journal-title":"Intern Med J"},{"key":"2020121103534544800_dkaa382-B4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2020121103534544800_dkaa382-B5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/INF.0000000000002048","article-title":"Itraconazole dosing and drug monitoring at a tertiary children\u2019s hospital","volume":"38","author":"Leong","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"2020121103534544800_dkaa382-B6","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1093\/jac\/dkx295","article-title":"Serum levels, safety and tolerability of new formulation SUBA-itraconazole prophylaxis in patients with haematological malignancy or undergoing allogeneic stem cell transplantation","volume":"72","author":"Lindsay","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020121103534544800_dkaa382-B7","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1093\/jac\/dkz303","article-title":"Clinical experience with new formulation SUBA\u00ae-itraconazole for prophylaxis in patients undergoing stem cell transplantation or treatment for haematological malignancies","volume":"74","author":"Nield","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2020121103534544800_dkaa382-B8"},{"key":"2020121103534544800_dkaa382-B9","volume-title":"The Harriet Lane Handbook: A Manual for Pediatric House Officers","author":"Tschudy","year":"2011","edition":"19th edn"},{"key":"2020121103534544800_dkaa382-B10","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1128\/AAC.00973-15","article-title":"Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and Sporanox capsule formulations in healthy subjects in fed and fasted states","volume":"59","author":"Abuhelwa","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020121103534544800_dkaa382-B11","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1378\/chest.08-2586","article-title":"Allergic bronchopulmonary aspergillosis","volume":"135","author":"Agarwal","year":"2009","journal-title":"Chest"},{"key":"2020121103534544800_dkaa382-B12","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1097\/INF.0000000000002324","article-title":"Endemic mycoses in children","volume":"38 Suppl 1","author":"Yeoh","year":"2019","journal-title":"Pediatr Infect Dis J"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/1\/249\/34855867\/dkaa382.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/1\/249\/34855867\/dkaa382.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T14:52:30Z","timestamp":1607698350000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/1\/249\/5905665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,15]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,9,15]]},"published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa382","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1]]},"published":{"date-parts":[[2020,9,15]]}}}